C-112 | Comparative Analysis of the DanGer Shock Trial to Randomized Cardiogenic Shock Trials and Real-World Registries
Magdi Zordok(Carney Hospital), Michael Megaly(St. John Medical Center), Muhammad Etiwy(Dartmouth–Hitchcock Medical Center), Sarju Ganatra(Lahey Hospital and Medical Center), Khaldoon Alaswad(Ford Motor Company (United States)), Kevin Buda(Hennepin Healthcare Research Institute), Sourbha S. Dani(Lahey Medical Center), Babar B. Basir, Emmanouil S. Brilakis(Minneapolis Heart Institute Foundation)
Journal of the Society for Cardiovascular Angiography & Interventions
May 1, 2025
Cited by 0
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589
Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention
|Circulation|2019|433
Outcomes After Complete Versus Incomplete Revascularization of Patients With Multivessel Coronary Artery Disease
|Journal of the American College of Cardiology|2013|389
Temporal Trends and Outcomes of Mechanical Complications in Patients With Acute Myocardial Infarction
|JACC: Cardiovascular Interventions|2019|374